Abstract | BACKGROUND: Second generation antipsychotic (SGA) use in bipolar disorder is common and has proven effective in short-term trials. There continues to be a lack of understanding of the mechanisms underlying many of their positive and negative effects in bipolar disorder. This study aimed to describe the metabolite profiles of bipolar subjects treated with SGAs by comparing to metabolite profiles of bipolar subjects treated with lithium, and schizophrenia subjects treated with SGAs. METHODS: Cross-sectional, fasting untargeted serum metabolomic profiling was conducted in 82 subjects diagnosed with bipolar I disorder ( n = 30 on SGAs and n = 32 on lithium) or schizophrenia (n = 20). Metabolomic profiles of bipolar subjects treated with SGAs were compared to bipolar subjects treated with lithium and schizophrenia subjects treated with SGAs using multivariate methods. RESULTS: CONCLUSIONS: The findings from this study require further validation in pre- and posttreated bipolar and schizophrenia subjects, but suggest that the pharmacometabolome may be diagnosis specific.
|
Authors | Kyle J Burghardt, Simon J Evans, Kristen M Wiese, Vicki L Ellingrod |
Journal | Clinical and translational science
(Clin Transl Sci)
Vol. 8
Issue 5
Pg. 432-40
(Oct 2015)
ISSN: 1752-8062 [Electronic] United States |
PMID | 26314700
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | © 2015 Wiley Periodicals, Inc. |
Chemical References |
- Antipsychotic Agents
- Biomarkers
- Lithium Compounds
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Biomarkers
(blood)
- Bipolar Disorder
(blood, diagnosis, drug therapy, psychology)
- Chi-Square Distribution
- Cross-Sectional Studies
- Discriminant Analysis
- Female
- Humans
- Least-Squares Analysis
- Lithium Compounds
(therapeutic use)
- Male
- Metabolomics
(methods)
- Middle Aged
- Multivariate Analysis
- Schizophrenia
(blood, diagnosis, drug therapy)
- Treatment Outcome
|